Market Access News | pharmaphorum

News

UK health chiefs urge caution over lockdown as COVID deaths ...

UK health chiefs have urged caution over any relaxation of lockdown rules amid signs that the impact of vaccination and social distancing regulations are beginning to work.

News

bluebird bio 'baffled' after NICE rejects beta-thalassaemia ...

It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular NHS use in first draft guidance.

News

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

UK government mulls lockdown review as it hits 15m COVID vac...

More than 15 million people in the UK have had their first coronavirus vaccine, described as a ‘significant milestone’ by prime minister Boris Johnson.

News

EU finalises order for 300 million more Pfizer/BioNTech COVI...

The European Union has rubber-stamped its order for a further 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine, according to press reports.

News

Labour accuses government of cronyism in COVID-19 contracts

The UK government’s massive spending on the coronavirus pandemic response has been “rife with conflicts of interest”, says the opposition Labour Party, and an independent watchdog should be

News

ViiV’s Rukobia cleared in EU as rescue HIV therapy

The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART

UK health chiefs urge caution over lockdown as COVID deaths ...

bluebird bio 'baffled' after NICE rejects beta-thalassaemia ...

UK government mulls lockdown review as it hits 15m COVID vac...

EU finalises order for 300 million more Pfizer/BioNTech COVI...

Labour accuses government of cronyism in COVID-19 contracts

ViiV’s Rukobia cleared in EU as rescue HIV therapy

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks